<SEC-DOCUMENT>0002007317-24-000038.txt : 20240131
<SEC-HEADER>0002007317-24-000038.hdr.sgml : 20240131
<ACCEPTANCE-DATETIME>20240131165727
ACCESSION NUMBER:		0002007317-24-000038
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240131
DATE AS OF CHANGE:		20240131

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		24583743

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anzalone Christopher Richard
		CENTRAL INDEX KEY:			0001423029
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		ARROWHEAD RESEARCH CORPORATION
		STREET 2:		201 SOUTH LAKE AVENUE, SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001423029</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0000879407</issuerCik>
      <issuerName>ARROWHEAD PHARMACEUTICALS, INC.</issuerName>
      <secFileNumber>001-38042</secFileNumber>
      <issuerAddress>
        <com:street1>177 E COLORADO BLVD</com:street1>
        <com:street2>SUITE 700</com:street2>
        <com:city>PASADENA</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>91105</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>626-696-4702</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Anzalone Christopher Richard</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Merrill Lynch</name>
        <address>
          <com:street1>75 Rockefeller Plz</com:street1>
          <com:street2>Flr 2</com:street2>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10019</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>57499</noOfUnitsSold>
      <aggregateMarketValue>1859992.22</aggregateMarketValue>
      <noOfUnitsOutstanding>107432210</noOfUnitsOutstanding>
      <approxSaleDate>01/31/2024</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <acquiredDate>02/06/2014</acquiredDate>
      <natureOfAcquisitionTransaction>Compensation</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Christopher Anzalone</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>57499</amountOfSecuritiesAcquired>
      <paymentDate>01/31/2024</paymentDate>
      <natureOfPayment>Compensation</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Christopher Anzalone</name>
        <address>
          <com:street1>177 E Colorado Blvd</com:street1>
          <com:street2>Ste. 700</com:street2>
          <com:city>Pasadena</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>91105</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <saleDate>12/21/2023</saleDate>
      <amountOfSecuritiesSold>12000</amountOfSecuritiesSold>
      <grossProceeds>342408.03</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Christopher Anzalone</name>
        <address>
          <com:street1>177 E Colorado Blvd</com:street1>
          <com:street2>Ste. 700</com:street2>
          <com:city>Pasadena</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>91105</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <saleDate>01/02/2024</saleDate>
      <amountOfSecuritiesSold>9952</amountOfSecuritiesSold>
      <grossProceeds>308622.17</grossProceeds>
    </securitiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>01/31/2024</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>03/22/2023</planAdoptionDate>
      </planAdoptionDates>
      <signature>Christopher Anzalone</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
